Please use this identifier to cite or link to this item:
https://doi.org/10.1038/s41537-018-0052-x
Title: | NEURAPRO: A multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders - Medium-term follow-up and clinical course | Authors: | Nelson, B Amminger, G.P Yuen, H.P Markulev, C Lavoie, S Schäfer, M.R Hartmann, J.A Mossaheb, N Schlögelhofer, M Smesny, S Hickie, I.B Berger, G Chen, E.Y.H De Haan, L Nieman, D.H Nordentoft, M Riecher-Rössler, A Verma, S Thompson, A Yung, A.R McGorry, P.D |
Keywords: | omega 3 fatty acid placebo adult Article Asia Australia case management clinical outcome cognitive behavioural case management cohort analysis controlled study deterioration double blind procedure Europe female follow up high risk patient human major clinical study male mental health mental health service multicenter study outcome assessment priority journal psychosis randomized controlled trial |
Issue Date: | 2018 | Citation: | Nelson, B, Amminger, G.P, Yuen, H.P, Markulev, C, Lavoie, S, Schäfer, M.R, Hartmann, J.A, Mossaheb, N, Schlögelhofer, M, Smesny, S, Hickie, I.B, Berger, G, Chen, E.Y.H, De Haan, L, Nieman, D.H, Nordentoft, M, Riecher-Rössler, A, Verma, S, Thompson, A, Yung, A.R, McGorry, P.D (2018). NEURAPRO: A multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders - Medium-term follow-up and clinical course. npj Schizophrenia 4 (1) : 11. ScholarBank@NUS Repository. https://doi.org/10.1038/s41537-018-0052-x | Rights: | Attribution 4.0 International | Abstract: | This study reports a medium-term follow-up of a randomised, double-blind, placebo-controlled trial of omega-3 polyunsaturated fatty acids (PUFA) in ultra-high risk for psychosis (UHR) patients. Primary outcomes of interest were transition to psychosis and symptomatic and functional outcome. A secondary aim was to investigate clinical predictors of medium-term outcome. Three hundred four UHR participants were recruited across 10 specialised early psychosis services in Australia, Asia, and Europe. The intervention consisted of 1.4 g/daily of omega-3 PUFA or placebo, plus up to 20 sessions of cognitive-behavioural case management (CBCM), over the 6-month study period, with participants receiving further CBCM sessions on basis of need between months 6-12. Mean time to follow-up was 3.4 (median = 3.3; SD = 0.9) years. There was a modest increase in transitions between 12-month and medium-term follow-up (11-13%) and substantial improvement in symptoms and functioning between baseline and follow-up, with no differences between the treatment groups. Most improvement had been achieved by end of the intervention. 55% of the sample received mental health treatment between end of intervention and follow-up. Omega-3 PUFA did not provide additional benefits to good quality psychosocial intervention over the medium term. Although most improvement had been achieved by end of intervention the substantial rates of post-intervention mental health service use indicate longer-term clinical need in UHR patients. The post-intervention phase treatment or the longer-term effect of CBCM, or a combination of the two, may have contributed to maintaining the gains achieved during the intervention phase and prevented significant deterioration after this time. © 2018 The Author(s). | Source Title: | npj Schizophrenia | URI: | https://scholarbank.nus.edu.sg/handle/10635/182067 | ISSN: | 2334265X | DOI: | 10.1038/s41537-018-0052-x | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_s41537-018-0052-x.pdf | 653.75 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License